Sanofi to Keep Options Open on Acquisitions, CEO Tells Investir
2014-05-03 10:06:44.807 GMT
By Tara Patel
May 3 (Bloomberg) -- Paris-based drugmaker will examine all
opportunities for external growth, although won’t make purchases
“at any price,” CEO Chris Viehbacher quoted as saying in
interview published in Investir.
* Sanofi needs to keep “strategic” financial reserve for
external growth, shareholder remuneration: Viehbacher
* Sanofi could have four or five R&D “key” partnerships in
future; may raise Regeneron stake to 30%: Viehbacher
* NOTE: Sanofi, Merck Each Said to Weigh Sale of Mature-Drug
Portfolios NSN N4YWIU6K50Y4 <GO>
For Related News and Information:
First Word scrolling panel: FIRST<GO>
First Word newswire: NH BFW<GO>
To contact the reporter on this story:
Tara Patel in Paris at +33-1-5365-5058 or
tpatel2@bloomberg.net
2014-05-03 10:06:44.807 GMT
By Tara Patel
May 3 (Bloomberg) -- Paris-based drugmaker will examine all
opportunities for external growth, although won’t make purchases
“at any price,” CEO Chris Viehbacher quoted as saying in
interview published in Investir.
* Sanofi needs to keep “strategic” financial reserve for
external growth, shareholder remuneration: Viehbacher
* Sanofi could have four or five R&D “key” partnerships in
future; may raise Regeneron stake to 30%: Viehbacher
* NOTE: Sanofi, Merck Each Said to Weigh Sale of Mature-Drug
Portfolios NSN N4YWIU6K50Y4 <GO>
For Related News and Information:
First Word scrolling panel: FIRST<GO>
First Word newswire: NH BFW<GO>
To contact the reporter on this story:
Tara Patel in Paris at +33-1-5365-5058 or
tpatel2@bloomberg.net